【结 构 式】 |
【分子编号】59137 【品名】 【CA登记号】 |
【 分 子 式 】C27H44O6 【 分 子 量 】464.64276 【元素组成】C 69.79% H 9.54% O 20.66% |
合成路线1
该中间体在本合成路线中的序号:(II)Ursodeoxycholic acid (I) was activated as the mixed anhydride (II) with ethyl chloroformate and triethylamine, and subsequently coupled with the triethylamine salt of taurine (III) to produce the title conjugated bile acid. Optionally, the mixed anhydride (II) was previously converted to the active phenol ester (V) by treatment with p-hydroxypropiophenone (IV), and subsequently condensed with taurine (III). Alternatively, ursodeoxycholic acid (I) was directly coupled to taurine (III) employing as the coupling reagents 2-isobutyl-N-isobutyloxycarbonyl-1,2-dihydroquinoline (IIDQ), diethylphosphorocyanidate (DEPC), or 2-ethoxy-N-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ) under microwave irradiation.
【1】 Momose, T.; et al.; An improved synthesis of taurine- and glycine-conjugated bile acids. Lipids 1997, 32, 7, 775. |
【2】 Dayal, B.; et al.; Microwave-induced rapid synthesis of bile acid conjugates. Synlett 1997, 8, 861. |
【3】 Bonadi, A.; Molinari, E.; Process for the preparation of taurine-conjugated bile acids. EP 0582891 . |
【4】 Reiner, A. (SkyePharma AG); Process for preparing ursodeoxycholic acid derivates and their inorganic and organic salts having therapeutic activity. EP 0272462 . |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(I) | 48093 | (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid | 128-13-2 | C24H40O4 | 详情 | 详情 |
(II) | 59137 | C27H44O6 | 详情 | 详情 | ||
(III) | 34828 | 2-amino-1-ethanesulfonic acid | 107-35-7 | C2H7NO3S | 详情 | 详情 |
(IV) | 58982 | 4'-Hydroxypropiophenone; 4-Hydroxypropiophenone; Ethyl 4-Hydroxyphenyl ktone; p-Hydroxypropiophenone; Paroxypropione | 70-70-2 | C9H10O2 | 详情 | 详情 |
(V) | 59138 | 4-propionylphenyl (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate | C33H48O5 | 详情 | 详情 |